RELMADA THERAPEUTICS, INC. Proceeds from Stock Options Exercised
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Stock Options Exercised of $101.50 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2026-06-30 was -$159.90M.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2026-03-31 was $160.00M.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2024-12-31 was $0.00.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2024-09-30 was $0.00.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2024 was $246.75K.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2022 was $703.72K, a 5.28% increase from fiscal 2021.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2021 was $668.43K, a 9.12% decline from fiscal 2020.
- RELMADA THERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2020 was $735.51K.
| Period end | Proceeds from Stock Options Exercised | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 9 month as first filed | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$159.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $101.50K 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $160.00M 10-Q · filed 2026-05-12 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $246.75K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $246.75K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $246.75K 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $246.75K 10-Q · filed 2025-05-12 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $286.18K derived: sum of 2 quarters · filed 2024-03-19 | $638.92K derived: sum of 3 quarters · filed 2024-03-19 | $703.72K 10-K · filed 2024-03-19 | ||
| 2022-09-30 | $286.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $638.92K derived: sum of 2 quarters · filed 2023-11-08 | $703.72K 10-Q · filed 2023-11-08 | $36.25K 10-Q · filed 2022-11-10 | $802.72K derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-07-07 | $52.70K 10-K · filed 2024-03-19 | |||||
| 2022-06-30 | $352.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $417.54K 10-Q · filed 2023-08-08 | $516.55K derived: sum of 3 quarters · filed 2023-08-08 | $568.70K derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $64.80K 10-Q · filed 2023-05-11 | $163.80K derived: sum of 2 quarters · filed 2023-05-11 | $215.96K derived: sum of 3 quarters · filed 2023-05-11 | $265.46K derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $151.16K derived: sum of 2 quarters · filed 2022-03-25 | $200.66K derived: sum of 3 quarters · filed 2022-03-25 | $668.43K 10-K · filed 2022-03-25 | ||
| 2021-09-30 | $52.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $101.65K derived: sum of 2 quarters · filed 2021-11-12 | $569.43K 10-Q · filed 2021-11-12 | $668.42K derived: sum of 4 quarters · filed 2022-03-25 | ||
| 2021-06-30 | $49.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $517.27K 10-Q · filed 2021-08-10 | $616.27K derived: sum of 3 quarters · filed 2022-03-25 | $722.14K derived: sum of 4 quarters · filed 2022-03-25 | ||
| 2021-03-31 | $467.77K 10-Q · filed 2021-05-12 | $566.77K derived: sum of 2 quarters · filed 2022-03-25 | $672.64K derived: sum of 3 quarters · filed 2022-03-25 | $1.13M derived: sum of 4 quarters · filed 2022-03-25 | ||
| 2020-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $204.87K derived: sum of 2 quarters · filed 2022-03-25 | $662.49K derived: sum of 3 quarters · filed 2022-03-25 | $735.51K 10-K · filed 2022-03-25 | ||
| 2020-09-30 | $105.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $563.50K derived: sum of 2 quarters · filed 2021-11-12 | $636.52K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $457.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $530.64K 10-Q · filed 2021-08-10 | ||||
| 2020-03-31 | $73.02K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |